Request Trial
jackie-7
26 November 2020Muireann Bolger

Five minutes with… Jacqueline Mulryne

Amid the unprecedented challenges presented by COVID-19, questions around the use of second medical use (SMU) patents have become increasingly pertinent. On Tuesday December 1, LSPN Connect ’s session: Addressing Second Medical Use Infringement: An Evaluation of Recent SMU Cases will examine a number of key issues relating to this pivotal area of life sciences IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Will Mounjaro and Zepbound get their first US generic rival?
30 June 2026   Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
Careers
King & Spalding continues hiring spree from pre-merged Winston
30 June 2026   The latest additions bring experience representing technology and medical device companies in complex patent and commercial disputes, with the firm extending its run of bringing in partners from Winston & Strawn before its merger.
Careers
Ashurst Perkins Coie opens its doors following landmark merger
29 June 2026   The newly combined transatlantic firm brings together more than 950 partners across 20 countries, uniting leading patent, trade secrets, life sciences, and tech practices.


Editor's picks

Pfizer’s US Paxlovid patent fight turns on a single error
Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026

Editor's picks

Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026

More features

Will Mounjaro and Zepbound get their first US generic rival?
King & Spalding continues hiring spree from pre-merged Winston
Ashurst Perkins Coie opens its doors following landmark merger
Merck KGaA agrees $11.3bn deal in major life sciences expansion
Pfizer’s US Paxlovid patent fight turns on a single error
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Novo secures website blocking to tackle fake weight-loss drugs
GLP-1 patents and Africa: The COVID-19 lessons we still have not learned